Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Celsion Corporation - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
CLSN
Nasdaq
2834
http://celsion.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Celsion Corporation
Celsion Corporation Reports First Quarter 2022 Financial Results and Provides Business Update
- May 16th, 2022 12:00 pm
Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates
- May 10th, 2022 12:30 pm
Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022
- May 9th, 2022 12:30 pm
Celsion's Formulated DNA Plasmid COVID-19 Vaccine Candidate Shows Activity Against Two Strains
- Apr 21st, 2022 7:24 pm
Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress
- Apr 21st, 2022 3:30 pm
Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial at 2022 AACR Annual Meeting
- Apr 14th, 2022 12:30 pm
Celsion Corporation to Highlight its PLACCINE Platform Technology During Oral Presentation at the World Vaccine Congress
- Apr 12th, 2022 12:30 pm
Celsion Corporation Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Apr 8th, 2022 8:30 pm
Celsion and Medidata to Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial
- Apr 6th, 2022 12:30 pm
CELSION CORPORATION ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
- Apr 6th, 2022 12:30 pm
CLSN: DSMB Recommends Continuing to Dose Patients in OVATION 2 Study…
- Apr 5th, 2022 10:15 am
Celsion Corporation Reported Cash Position of $56.9 million at December 31, 2021
- Apr 1st, 2022 12:00 pm
Celsion Corporation Reports 2021 Financial Results and Provides Business Update
- Mar 31st, 2022 12:30 pm
Celsion Corporation to Hold Year-End 2021 Financial Results and Business Update Conference Call on Thursday, March 31, 2022
- Mar 24th, 2022 1:00 pm
Celsion Receives $1.4 Million from Sale of its New Jersey State Net Operating Losses
- Feb 28th, 2022 2:00 pm
Celsion Corporation Announces Stock Consolidation
- Feb 28th, 2022 1:30 pm
Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
- Feb 17th, 2022 1:30 pm
Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate
- Jan 31st, 2022 1:00 pm
Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock
- Jan 13th, 2022 10:30 pm
Celsion Corporation Invited to Present Poster at Cytokine-Based Cancer Immunotherapies Summit
- Nov 29th, 2021 1:30 pm
Scroll